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Role of calcium-phosphorous disorders in the progression of
renal failure. Among factors related to disturbed calcium-
phosphate metabolism in chronic kidney disease, the following
must be mainly considered as potential culprits in the progres-
sion of renal dysfunction: hyperphosphatemia, hyperparathy-
roidism, lack of active vitamin D, and possibly excess of the
phosphaturic hormone FGF 23.
Early experimental work suggested a parathyroid hormone
(PTH)-independent beneficial role of phosphate restriction
on progression in rats (animals with physiologic hyperphos-
phatemia), so that the generalization of the data is uncertain.
Recent observational studies also found a correlation between
S-phosphate and progression, but it remains uncertain whether
the relationship is causal.
There is very little direct experimental or clinical evidence for
a role of PTH in accelerating progression, although the PTH1
receptor is expressed in podocytes and PTH affects podocyte
function (i.e., Kf). It is undoubtedly a candidate that requires
more sophisticated investigation.
Recently, it has been shown that progression is significantly
attenuated by calcimimetics (and equally by parathyroidec-
tomy), but it is currently impossible to exclude a confounding
effect of lower blood pressure values.
The most solid evidence for an impact on progression exists
for active vitamin D. In the past, it was widely assumed that
vitamin D was “nephrotoxic.” In retrospect, nephrotoxicity was
the result of hypercalcemia. Recent evidence is overwhelming
that 1,25(OH)2D3 and its analogues attenuate progression in
noninflammatory and inflammatory models of chronic kidney
disease. The main target cells identified so far are podocytes and
mesangial cells.
It is currently unknown whether the novel phosphaturic hor-
mones have an impact on progression.
Compared with the well-known effects of high blood
pressure or proteinuria, disorders of the calcium-
phosphate metabolism have not attracted much attention
as potential causal factors in the genesis of progression
of chronic kidney disease. Undoubtedly, their effect, if
anything, has been minor compared with the aforemen-
tioned factors, but is not necessarily trivial given that even
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optimal treatment of hypertension and proteinuria fails
to consistently halt progression.
THE POTENTIAL ROLE OF
HYPERPHOSPHATEMIA
Beneficial effects of dietary phosphate restriction have
mainly been shown in two experimental models (i.e.,
nephrotoxic nephritis [1, 2] and remnant kidney model
[3]). For several reasons these studies are complex. The
rat has physiologically higher serum phosphate concen-
trations than man. It remains uncertain to what extent
the results in rats can be generalized to other species.
Phosphate restriction causes secondary changes in cal-
cemia and parathyroid hormone (PTH) concentrations.
Although the latter confounder was carefully addressed
in the study from Tomford et al [2], it still remains unclear
whether the salutary effect of phosphate restriction is me-
diated via changes in renal hemodynamics, via less re-
nal calcification or changes of cellular calcium/phosphate
concentrations, respectively, or via other factors [4, 5].
Almost no clinical data are available on this issue.
In the Irbesartan Diabetic Nephropathy Trial study [6],
we noted that by proportional hazards regression analy-
sis, the relative risk of reaching a renal end point was
higher by a factor of 1.8 in hyperphosphatemic diabetic
patients (unpublished data), but it is uncertain whether
the relationship is causal or whether it is explained by
association with other (unrecognized) factors.
Consequently, it remains unclear whether the imbal-
ance between dietary phosphate load and renal excre-
tory capacity has an impact on progression and, if so,
whether such effect is the direct consequence of hyper-
phosphatemia or the indirect result of changes in PTH,
tissue calcium, or other factors.
THE POTENTIAL ROLE OF
HYPERPARATHYROIDISM
There are many suggestive hints that hyperparathy-
roidism might be a plausible candidate for acceleration
of progression. Both in the rat [7] and the dog [8], PTH
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caused significant lowering of Kf, potentially pointing
to the podocyte as the target structure. At least in the
thyroparathyroidectomized rat, low PTH doses caused a
decrease in single nephron glomerular filtration rate with-
out any change in QA, PGC, or P. Podocytes express
very intensely a unique 4.0 transcript of the PTH1 recep-
tor for PTH and/or PTH-related protein (PTHrp) [9].
Both PTHrp and the PTH receptor (PTH1R) are ex-
pressed in cultures of differentiated podocytes [10]. In
these cells, PTH and PTHrp selectively increase cellular
cyclic adenosine monophosphate (cAMP) without any
change in Ca++. cAMP, in turn, has been shown to ac-
tivate specific Cl−channels in such podocytes [11]. As
shown in prostaglandin-induced changes in cAMP, this
may well result in alterations of the cytoskeleton and in
functional changes of podocytes [12].
A further level of complexity is introduced by the fact
that in renal damage models, PTHrp, a partial homologue
of PTH, is upregulated, while the receptor common for
both hormones (PTH1R) is downregulated [13]; it is un-
known whether this is the direct result of renal injury
or the consequence of exposure to angiotensin II. An-
giotensin II [14], endothelin-1, and transforming growth
factor-b (TGF-b) have been shown to upregulate PTHrp
[15]. Because PTHrp and PTH, in turn, stimulate renin
production [16], the possibility of a positive feedback ex-
ists, at least theoretically.
What is the clinical and experimental evidence for an
adverse effect of PTH on progression? It is of interest
that in the huge national sample of 4471 Swedish patients
undergoing surgery for primary hyperparathyroidism,
serum creatinine, low glomerular filtration rate, and low
concentrating capacity predicted premature death post-
operatively. Uremia as a cause of death, however, was
not noted [17], as one would anticipate if PTH were a
major factor accelerating progression. One experimental
study suggested that PTH accelerated progression and
reduced survival in the remnant kidney model, at least
when animals were on a high (40%) protein intake [18].
Parathyroidectomy increased survival, abrogated the in-
crease in renal mass and renal calcium content, abrogated
the increase in serum cholesterol, and significantly atten-
uated the increase in serum creatinine and blood urea
nitrogen. In contrast to our study [19], administration of
1,25(OH)2D3 worsened renal function and reversed the
protection provided by parathyroidectomy (PTX). This
study would be consistent with the notion that, at least
under conditions of high protein intake, PTH aggravates
progression.
THE EFFECT OF CALCIMIMETICS ON
PROGRESSION
Ogata et al [20] studied subtotally nephrectomized rats
that received either the calcimimetic R-568 or were sub-
jected to parathyroidectomy. Both interventions were as-
sociated with a lesser increase in serum creatinine con-
centration, a lesser increase in urine albumin excretion,
and with less abnormal indices of glomerulosclerosis or
tubulointerstitial lesions. Apart from this, less cardiac fi-
brosis and arteriolar thickening were observed as well,
in line with our previous findings of a permissive role of
PTH in the genesis of these lesions [21]. Ogata et al also
found that if PTH was lowered, low-density lipoprotein
cholesterol concentrations were less. These findings are
of interest in light of recent observations that in renal pa-
tients parathyroidectomy improves survival by lowering
the rate of cardiovascular death [22, 23]. Unfortunately,
the data from Ogata et al are not unequivocal evidence for
a direct renoprotective role of lowering of PTH, because
both R-568 and parathyroidectomy lowered blood pres-
sure in uremic rats. Ongoing studies must clarify whether
the effects of lower PTH and lower blood pressure can
be dissociated.
THE EFFECT OF ACTIVE VITAMIN D
Undoubtedly, the most solid evidence for an impact on
progression exists for active vitamin D. In the past, there
had been concerns that vitamin D might be “nephro-
toxic,” because renal failure occurred not infrequently in
patients on high doses of vitamin D—in retrospect, almost
certainly as a result of hypercalcemia and hypercalciuria.
Although recently it had still been claimed that active
vitamin D was nephrotoxic [24], we reasoned that—on
the contrary—it might be renoprotective. This notion
was based on the finding from Nakagura et al [25] that
1,25(OH)2D3 as well as its analogues inhibited cell pro-
liferation in a human renal cell carcinoma cell line (KU-
2), which exhibited specific binding of 1,25(OH)2D3,.
This observation was tantalizing, because compensatory
growth of remnant nephrons occurs in injured kidneys
and is thought to contribute to progressive renal dysfunc-
tion [26]. Furthermore, there is evidence that active vi-
tamin D suppresses expression of renin [27]—of obvious
importance for progression.
We therefore examined the effect of 1,25(OH)2D3
on renal compensatory growth after uninephrectomy in
vitamin D replete adult rats [26]. Five days after uni-
nephrectomy, the weight of the contralateral kidney had
increased by 25% and had reached a plateau by day 7,
primarily as the result of cell proliferation, with an in-
crease in cell number as evaluated by stereologic mea-
surements in perfusion-fixed kidneys. A low dose of daily
1,25(OH)2D3, increasing the plasma concentration by a
factor of 3.3, attenuated the increase in kidney weight and
significantly reduced the number of mitoses in the kidney,
particularly in the proximal tubule. This was a direct ef-
fect of vitamin D, because it was also demonstrable in
parathyroidectomized animals given a constant infusion
of exogenous PTH by osmotic minipump. Thus, changes
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of 1,25(OH)2D3 concentrations in a physiologically rele-
vant range modulate compensatory growth of the kidney.
What about the effect of active vitamin D in (nonin-
flammatory) models of renal damage? Several experi-
mental studies document a benefit of either 1,25(OH)2D3
[19] or 22-oxacalcitriol in comparison with 1,25(OH)2D3
[28, 29].
The rationale for our study was that active vitamin D
inhibited cell proliferation in vivo [26] as well as in hu-
man mesangial cell cultures [30] and a proximal tubular
cell line [31]. In mesangial cells, 1,25(OH)2D3 dose-
dependent, inhibited proliferation during both logarith-
mic growth and at confluence was associated with the
appearance of electron-dense, membrane-bound lysoso-
mal granules [30]. Proximal tubular cells [31] are of inter-
est, because it has been speculated that in renal disease
diminished local production of 1,25(OH)2D3 facilitates
interstitial fibrosis by permitting fibroblasts to escape
from the inhibitory control by 1,25(OH)2D3 on cell pro-
liferation.
It has also been shown [32] that the vitamin D analogue
11-oxacalcitriol–mediated inhibition of cell proliferation
is neutralized by administration of TGF-b antibody. 11
oxacalcitriol did not affect production of TGF-b , but in-
creased the expression of the TGF receptor II, which me-
diated phenotypic alterations.
In the study from Schwarz et al [19], administration
of 3 ng/100 body weight/day of 1, 25(OH)2D3 by os-
motic minipump did not affect systolic blood pressure
and caused only a transient diminution of weight gain.
After moderate controlled surgical resection, reducing
the nephron number from 33,000 to 12,000 per kidney,
a significant increase of glomerular volume, glomeru-
lar sclerosis index, and albumin excretion was noted in
solvent-treated animals. This was accompanied by the ex-
pression of TGF-b , predominantly in proximal tubules.
Immunohistology of the proliferating cell nuclear anti-
gen (PCNA) documented intense cell proliferation. All
these indices were definitely ameliorated by low-dose
1,25(OH)2D3. This effect was independent of PTH, be-
cause an inhibitory effect of 1,25(OH)2D3 on cell prolifer-
ation (i.e., PCNA expression) could also be documented
in parathyroidectomized rats maintained on nonhyper-
calcemic doses of exogenous PTH. Hirata et al [28] also
studied subtotally nephrectomized rats and compared the
effect of a low and high dose of oxacalcitriol, respectively.
Oxacalcitriol significantly decreased the urinary albumin
excretion, the increase in serum creatinine concentration,
the glomerulosclerosis index, and glomerular volume as
well as glomerular cell number. More recently, in a di-
rect head-on comparison, Sanai et al [29] used another
noninflammatory model of renal damage (i.e., adria-
mycin-induced progressive renal failure). Two doses
of oxacalcitriol and 1,25(OH)2D3 were compared. A
higher death rate, higher serum creatinine concentration,
more intense tubulointerstitial changes, calcium de-
posits, as well as glomerular and tubulointerstitial ex-
pression of TGF-b were found in animals treated with
1,25(OH)2D3 compared with oxacalcitriol. These effects
of 1,25(OH)2D3 were, however, clearly dose-dependent,
and the contribution of calcium deposition in the kidney
was an important confounder.
Is the podocyte the major target of active vitamin D?
In the past, the effects of active vitamin D on mesan-
gial cell proliferation and function had been emphasized
[19, 28, 30, 32]. More recently, however, the podocyte
has been recognized as a key cell in the development of
glomerular injury [33]. To explore the effect of active vita-
min D on this target cell, Kuhlmann et al [34] compared
subtotally nephrectomized rats receiving either solvent
or 1,25(OH)2D3 (3 ng/100 body weight/day) by subcuta-
neous osmotic minipumps. The expression of PCNA, the
cyclin-kinase inhibitor p-27, and desmin was assessed as
well as the cellular composition of the glomerulus. Spe-
cific attention was paid to podocyte number, volume,
and ultrastructure. The low nonhypercalcemic dose of
1,25(OH)2D3 failed to affect systolic blood pressure, but
decreased the weight of the kidney remnant, and reduced
glomerular capillary closure and the number of mesan-
gial cells. Furthermore, the mean podocyte number per
glomerulus and podocyte volume was less reduced, and
podocytes’ ultrastructure was less deranged compared
with solvent-treated animals. It is uncertain whether the
reduced number of podocytes in solvent- treated ani-
mals reflects apoptosis of podocytes or whether it re-
flects desquamation of vital podocytes by abrogation of
the attachment of the basal membrane via alpha-3-b-1-
integrin or alpha-dystroglycan [33]. Because the increase
in glomerular volume after subtotal nephrectomy was
completely abrogated by 1,25(OH)2D3 treatment, it is
conceivable that the domains controlled by individual
podocytes were not expanded, so that the compensatory
need for podocytes to cover a greater filtering surface
was prevented. Alternatively, 1,25(OH)2D3 may have di-
rectly improved podocyte viability. At any rate, the bene-
ficial effect of active vitamin D on podocytes is illustrated
by considerably less staining for the cytokeratine desmin,
an indicator of incipient podocyte injury. Interestingly,
podocytes stained positive for PCNA (which does not
necessarily prove cell proliferation in these postmitotic
cells, which are unable to undergo cell replication by mito-
sis) upregulated expression of the cyclin-kinase inhibitor
p-27. This observation is in line with the effect of vita-
min D in other cell systems such as in HL-60-leucemia.
It is known that in mice and humans, immature prolif-
erating podocytes do not express p27 and p57. Podocyte
differentiation coincides with a marked increase in the
expression of the CDK inhibitors p-27 and p-57 [35]. The
cycline kinase inhibitors are presumably not required for
normal glomerular development, because p-21 and p-27
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knock-out mice have normal kidneys, but complement-
induced injury to mature podocytes upregulates both
cyclin-A and CDK-2, and also p-21 and p-27. This ob-
servation suggests that podocytes engage the cell cycle,
but these postmitotic cells are then prevented from com-
pleting the cell cycle because of upregulation of the p-21
and p-27 inhibitors.
Because of the immune modulatory effects of active
vitamin D [36, 37], the interpretation of studies in in-
flammatory models of renal damage are more difficult.
In the model of active Heyman nephritis [38], Lewis rats
were given 1,25(OH)2D3 or cyclosporin A, the latter as
a control for potential immunosuppressive effects. The
high dose of 1,25(OH)2D3 of 0.5 lg/kg/body weight on
alternate days during the first 13 days after active immu-
nization reduced proteinuria. The effect was comparable
in magnitude to the reduction seen with cyclosporin A.
The level of autoantibodies was lower, and the size of im-
mune deposits was smaller, but the dose of 1,25(OH)2D3
was pharmacologic and increased serum calcium concen-
tration.
In the Thy-1 model of mesangioproliferative nephri-
tis [39, 40], animals receiving 1,25(OH)2D3 showed less
proteinuria, less interleukin-6 excretion, reduced glome-
rular diameters, and decreased recruitment of inflamma-
tory cells (neutrophils, monocytes) as well as attenuated
proliferation of resident glomerular cells (PCNA tech-
nique). The apoptotic response in the phase of repara-
tion was preserved, however. In the same model, the
vitamin D analogue 2-oxacalcitriol was compared with
1,25(OH)2D3. Both significantly inhibited mesangial cell
proliferation and development of glomerulosclerosis and
albuminuria; untreated animals showed increased ex-
pression of type I and type IV collagen and alpha smooth
muscle actin, and this was abrogated by either oxacal-
citriol or 1,25(OH)2D3. Furthermore, the expression of
TGF-b was reduced by both agents [40].
Active vitamin D is a member of the steroid recep-
tor superfamily. It is of interest that retinoic acids, de-
rived from vitamin A, act via specific receptors, retinoid
A (RAR) and retinoid X. These are expressed in the
kidneys of rats and humans. Agonists specifically acting
on these two receptors have been shown to have potent
antiproliferative, anti-inflammatory, and antifibrotic ac-
tions. It has also been documented that they alleviate
renal damage not only in acute and chronic glomeru-
lonephritis, but also in noninflammatory models of renal
damage, such as ureteral ligation and subtotal nephrec-
tomy [41, 42]. This finding is not without interest, be-
cause the action of the vitamin D receptor is mediated by
the heterodimer vitamin D receptor/retinoid X. The role
of potential interactions between active vitamin D and
retinoids is currently unclear.
Undoubtedly, of all the factors of deranged calcium
and phosphate metabolism in chronic kidney disease, the
evidence for a role on progression is strongest for ac-
tive vitamin D. Nonhypercalcemic doses of active vita-
min D attenuate progression in noninflammatory as well
as inflammatory models of renal damage. Podocytes are
particularly important targets for the beneficial action
of active vitamin D. The immune modulatory and an-
tifibrogenic actions of active vitamin D may be advanta-
geous in glomerulonephritis and chronic renal allograft
nephropathy [43]. We are aware of the limitation that
these conclusions are based exclusively on animal mod-
els. Controlled observations in human renal disease are
not available, but it is of note that the initial controlled
trials on 1,25(OH)2D3 showed at least no deterioration of
renal function, attesting to the safety of this intervention.
Reprint requests to Prof. Eberhard Ritz, Departments Inter-
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